Dr. Martens (LON:DOCS) Insider Acquires £149.31 in Stock

Dr. Martens plc (LON:DOCS) insider Giles Wilson purchased 237 shares of the stock in a transaction on Wednesday, November 11th. The shares were purchased at an average cost of GBX 63 per share, with a total value of £149.31.

Dr. Martens Trading Down 2.4%

LON:DOCS traded down GBX 1.30 on Friday, hitting GBX 52.80. 8,973,928 shares of the stock were exchanged, compared to its average volume of 6,087,294. The stock has a fifty day moving average of GBX 66.38 and a 200-day moving average of GBX 69.35. The stock has a market cap of £505.44 million, a PE ratio of 22.00, a PEG ratio of 6.40 and a beta of 0.26. The company has a current ratio of 2.34, a quick ratio of 1.13 and a debt-to-equity ratio of 121.89. Dr. Martens plc has a fifty-two week low of GBX 51 and a fifty-two week high of GBX 90.

Dr. Martens (LON:DOCS) last issued its earnings results on Thursday, November 12th. The company reported GBX (1) earnings per share (EPS) for the quarter. The firm had revenue of £290.40 million for the quarter. Dr. Martens had a return on equity of 6.89% and a net margin of 3.11%. As a group, equities analysts expect that Dr. Martens plc will post 2.58 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Berenberg Bank reiterated a “buy” rating and set a GBX 110 price objective on shares of Dr. Martens in a research note on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Dr. Martens has a consensus rating of “Moderate Buy” and a consensus price target of GBX 105.

Dr. Martens News Summary

These are some of the DOCS news items that stood out recently:

• Positive Sentiment: Insiders Giles Wilson and Ije Nwokori each bought a small number of shares at GBX 63. The purchases may signal confidence, though each transaction was worth only about £150. Article: Dr. Martens insider buying
• Negative Sentiment: Half-year revenue fell 9%, while boot sales dropped 20%, with unusually hot summer weather cited as a drag on demand. Management warned that the trading season ahead is crucial, putting the holiday period at the center of hopes for recovery. Article: Dr Martens warns trading season is crucial Article: Dr Martens boot sales fall
• Negative Sentiment: The reported quarter included a loss of GBX 1 per share and revenue of £290.4 million; the results add to investor focus on whether demand can improve. Article: Dr Martens quarterly results

Dr. Martens Company Profile

Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.